Selected article for: "human immunodeficiency and membrane fusion"

Author: Yadi Zhou; Yuan Hou; Jiayu Shen; Yin Huang; William Martin; Feixiong Cheng
Title: Network-based Drug Repurposing for Human Coronavirus
  • Document date: 2020_2_5
  • ID: b4mdiont_29
    Snippet: Toremifene (Z = -3.23, Figure 5A ), the first generation of nonsteroidal SERM, exhibits potential effects in blocking various viral infections, including MERS-CoV, SARS-CoV, and Ebola virus in established cell lines [16, 35] . Interestingly, different from the classical ESR1-related antiviral pathway, toremifene prevents fusion between the viral and endosomal membrane by interacting with and destabilizing the virus membrane glycoprotein, and even.....
    Document: Toremifene (Z = -3.23, Figure 5A ), the first generation of nonsteroidal SERM, exhibits potential effects in blocking various viral infections, including MERS-CoV, SARS-CoV, and Ebola virus in established cell lines [16, 35] . Interestingly, different from the classical ESR1-related antiviral pathway, toremifene prevents fusion between the viral and endosomal membrane by interacting with and destabilizing the virus membrane glycoprotein, and eventually inhibiting viral replication [36] . As shown in Figure 5B , toremifene potentially affects several key host proteins associated with HCoV, such as RPL19, HNRNPA1, NPM1, EIF3I, EIF3F, and EIF3E [37, 38] . Equilin (Z = -2.52 and GSEA score = 3), an estrogenic steroid produced by horses, also has been proven to have moderate activity in inhibiting the entry of Zaire Ebola virus-glycoprotein and human immunodeficiency virus (ZEBOV-GP/HIV) [17] . Altogether, network-predicted SERMs (such as toremifene and equilin) offer potential repurposable candidates for HCoVs.

    Search related documents:
    Co phrase search for related documents